DANIEL D BURGESS
CIK 1239650 · COO/CFO · last filed 2026-01-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
6
Total Filings
51
Lifetime Open-Market Net
-$535.6K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 0 | $221.38 | $0 | $48.0K | 14 | 2026-01-07 |
| ABUS | Director | — | $5.09 | — | $0 | 9 | 2024-05-24 |
| Nabriva Therapeutics plc (NBRV) Delisted | Director | 415 | $1.42 | $589 | $95.5K | 8 | 2022-08-04 |
| SANTARUS INC (SNTS) Delisted | Director | 0 | — | — | -$666.7K | 14 | 2013-06-12 |
| MBRX | Director | — | $0.65 | — | $0 | 3 | 2009-06-24 |
| Harbor BioSciences, Inc. (HEPH) Delisted | COO/CFO | 12,209 | — | — | -$12.4K | 1 | 2007-02-15 |
Recent Filings · Page 2 of 6
51 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-08-04 | Nabriva Therapeutics plc (NBRV) Delisted | Sell (S) | −1,125 | -$1.4K | EDGAR |
| 2021-07-30 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | +17,500 | $0 | EDGAR |
| 2021-06-24 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-07 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2020-07-31 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | +17,500 | $0 | EDGAR |
| 2020-06-25 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-01 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2019-08-20 | ABUS | Grant (A) | — | $0 | EDGAR |
| 2019-08-01 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-27 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.